Collaboration combines clinical research expertise with artificial intelligence capabilities to help drug developers better understand the probability of clinical success for their assets
Pharma in Korea receives a 7% increase in ‘growth potential’ category according to the CPHI Annual Survey findings
Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy
The CHMP’s recommendation will now be reviewed by the European Commission for marketing authorization in the European Union
Mage Biologics to develop a monoclonal antibody targeting ulcerative colitis
The Long-term Safety Trial was approved to be conducted by China National Medical Products Administration (NMPA) on 18 April 2023
Approval to dramatically change CAR-T therapies landscape
SMPA's diverse portfolio includes six marketed products and a robust pipeline of early- to late-stage assets
Rare childhood cancer subtype, Ph+ ALL, is found in 3-4% of pediatric cases and 25% of adult cases
The positive safety review from the DSMB enables the trial to move forward as planned, with an estimated completion date in December 2023
Subscribe To Our Newsletter & Stay Updated
